Shots:
- Teva Pharmaceuticals and Prestige Biopharma have signed a license and supply agreement to commercialize Tuznue (trastuzumab), a Herceptin biosimilar, in most European markets
- As per the deal, Teva will market and distribute Tuznue in most European markets, while Prestige Biopharma will handle production and supply from its EU-GMP-certified facilities
- Tuznue, biosimilar of Herceptin, with comparable efficacy and safety, approved for treating HER2-positive metastatic and early breast cancer, as well as metastatic gastric cancer
Ref: Teva | Image: Teva and Prestige Biopharma | Press Release
Related News:- Teva Reports the Data from the P-IV (PEARL) Study of Ajovy (fremanezumab) for Chronic and Episodic Migraine Prevention
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
